| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | MG-132 | CTRPv2 | pan-cancer | AAC | 0.037 | 0.6 |
| mRNA | tamatinib | CTRPv2 | pan-cancer | AAC | 0.022 | 0.6 |
| mRNA | Obatoclax Mesylate | GDSC1000 | pan-cancer | AAC | 0.02 | 0.6 |
| mRNA | Bortezomib | GDSC1000 | pan-cancer | AAC | -0.027 | 0.6 |
| mRNA | GSK1120212 | CTRPv2 | pan-cancer | AAC | -0.028 | 0.6 |
| mRNA | PD-0332991 | GDSC1000 | pan-cancer | AAC | -0.019 | 0.6 |
| mRNA | carboplatin:etoposide (40:17 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.017 | 0.6 |
| mRNA | PD-0325901 | GDSC1000 | pan-cancer | AAC | 0.018 | 0.6 |
| mRNA | cimetidine | CTRPv2 | pan-cancer | AAC | -0.038 | 0.6 |
| mRNA | 1S,3R-RSL-3 | CTRPv2 | pan-cancer | AAC | -0.019 | 0.6 |